HIV therapeutics market to reach $28 billion in 2029

Injectables are driving the growth because they can be taken less frequently and adherence is a problem with oral medications.

Treatments for the human immunodeficiency virus (HIV) are expected to reach $28 billion in sales in 2029, driven by injectable medications, a recent report says.

The total HIV therapeutics market was worth an estimated $22.9 billion across 7 major markets globally in 2019, according to GlobalData’s ‘HIV Therapeutics: Global Drug Forecast and Market Analysis to 2029’ report.

The 7 markets include the U.S., France, Germany, Italy, Spain, the United Kingdom, and Japan,

Related: Viiv Healthcare’s Cabenuva will be available in the U.S. in February

Sales of injectable therapies are expected to exceed $1.8 billion in 2029. Injectables provide a viable alternative to oral medications since patients may not remember to take their medications, said Magdalene Crabbe, MA, senior ophthalmology and infectious diseases analyst at GlobalData, in a press release.

“The launch of STRs [single-tablet regimens of combination antiretroviral drugs] revolutionized the treatment landscape of HIV and met major unmet needs by increasing patient compliance and improving the safety and tolerability profiles of antiretroviral drugs,” Crabbe said.

However, there are challenges with STRs, according to Crabbe. “A key component of multiple drugs is tenofovir disoproxil fumarate (TDF), which has been linked to osteoporosis and kidney disease. There are also people who don’t remember to take their medication, and people who feel embarrassed about living with HIV, which lowers compliance,” she said.

Related: FDA clears first-in-class HIV-1 treatment

Roche’s Fuzeon (enfuvirtide) was the first subcutaneously-administrable drug to be approved for the treatment of HIV-infected patients. “However, the fact that the drug is administered multiple times daily has led to difficulties with adherence and the emergence of injection-site related adverse events such as lipohypertrophy, erythema and pruritus,” GlobalData said.

By 2029, other injectable therapies such as CytoDyn’s leronlimab and Gilead Sciences’ Lenacapavir will be available in the market, according to Crabbe.

In addition, TaiMed’s Trogarzo (ibalizumab), which is an intravenously administered monoclonal antibody, launched in the U.S. in 2018 and in Europe in 2020.

There is also an increased market for HIV treatments due to the increase in cases of the disease. GlobalData projects that the diagnosed prevalent HIV cases in the seven major markets will increase from 1.87 million in 2019 to 2.1 million in 2029.

The U.S. will have the highest number of diagnosed prevalent cases of HIV in 2029 with more than 1.4 million, according to GlobalData’s report, Human Immunodeficiency Virus (HIV): Epidemiology Forecast to 2029’,

Read more: Gilead snags approval for second HIV-1 prevention drug